When was Stealth BioTherapeutics founded?

Stealth BioTherapeutics was founded in 2007 and raised its 1st funding round 11 years after it was founded.

Where is Stealth BioTherapeutics located?

Stealth BioTherapeutics is headquartered in Newton, United States.

Who is the current CEO of Stealth BioTherapeutics?

Reenie McCarthy of Stealth BioTherapeutics.

How many employees does Stealth BioTherapeutics have?

As of Jul 31, 2026, the latest employee count at Stealth BioTherapeutics is 62.

Is Stealth BioTherapeutics a funded company?

Stealth BioTherapeutics is a funded company, having raised a total of $100M across 2 funding rounds to date. The company's 1st funding round was a $***** PE round, raised on Jan 18, 2018.

When was the latest funding round of Stealth BioTherapeutics?

Stealth BioTherapeutics' latest funding was a $***** Post IPO round on Apr 13, 2020, with participation from 1 investor. Its primary sector is Rare Diseases. In United States, the Rare Diseases sector has seen $1.05B in funding in 2026 to date.

Where does Stealth BioTherapeutics rank among its competitors?

Stealth BioTherapeutics ranks 40th amongst 283 active competitors, of which 77 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was BridgeBio, which secured $200M in Apr, 2024.

Who are the top competitors of Stealth BioTherapeutics?

Stealth BioTherapeutics' top competitors include BridgeBio, Alnylam and PTC Therapeutics. Among them, BridgeBio secured the most recent funding round in April, 2024.

Stealth BioTherapeutics - 2026 Company Profile, Team, Funding & Competitors

Stealth BioTherapeutics is an acquired company based in Newton (United States), founded in 2007. It operates as a Developer of peptide therapy to treat rare mitochondrial diseases and its dysfunction-related disorders. Stealth BioTherapeutics has raised $100M in funding from Nan Fung Life Sciences. The company has 283 active competitors, including 77 funded and 98 that have exited. Its top competitors include companies like BridgeBio, Alnylam and PTC Therapeutics.

Company Details

Developer of peptide therapy to treat rare mitochondrial diseases. The company has developed Mitochondrial Carrier Technology(MCT) to deliver biologically active candidates to mitochondria. Its lead candidate Elamipretide is a mitochondrial-targeting tetrapeptide that binds and stabilizes cardiolipin to promote electron transfer and prevent apoptosis. It has the potential in treating skeletal, ocular, and cardiorenal disorders caused by mitochondrial dysfunction.

Website: stealthbt.com
Social
Email ID: *****@StealthBT.com

Key Metrics

Founded Year

2007

Location

Newton, United States

Stage

Acquired

Total Funding

$100M in 2 rounds

Latest Funding Round

Post IPO, Apr 13, 2020, $*****

Investors

Nan Fung Life Sciences & 9 more

Ranked

40^th among 283 active competitors

Employee Count

62 as on Jul 31, 2026

Similar Companies

BridgeBio & 317 more

Exit Details

Acquired by Morningside (Aug 01, 2022)

View Stealth BioTherapeutics' full profile

Stealth BioTherapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Stealth Biotherapeutics Inc. CIN: 26-1512085 , United States, Active	Oct 21, 2007	-	31 (As on Dec 31, 2020)	-

Stealth BioTherapeutics got acquired by Morningside on Aug 01, 2022.

Click here to take a look at Stealth BioTherapeutics's acquisition in detail

Stealth BioTherapeutics has raised a total funding of $100M over 2 rounds. Its first funding round was on Jan 18, 2018. Its latest funding round was a Post IPO round on Apr 13, 2020 for $*****. 1 investor participated in its latest round. Stealth BioTherapeutics has 10 institutional investors.

Here is the list of recent funding rounds of Stealth BioTherapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 13, 2020	6289571	Post IPO	6913616	4347725	2943507	2069872
Jan 18, 2018	2273779	PE	5014757	7450042	Nan Fung Life Sciences	Atlantis Investment Management & 6 more

Access funding benchmarks and valuations. Sign up today!

View details of Stealth BioTherapeutics's funding rounds and investors

Stealth BioTherapeutics' employee count trend

Stealth BioTherapeutics has 62 employees as of Jul 26. Here is Stealth BioTherapeutics's employee count trend over the years:

Employee count trend for Stealth BioTherapeutics

Uncover Stealth BioTherapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Stealth BioTherapeutics include BridgeBio, Alnylam and PTC Therapeutics. Here is the list of Top 10 competitors of Stealth BioTherapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BridgeBio 2015, Palo Alto (United States), Public	Developer of therapeutics for the treatment of genetic diseases	$434M	Viking Global Investors, KKR & 20 others	81/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Alexion 1992, Zurich (Switzerland), Acquired	Developer of therapies for patients with devastating and rare diseases	$133M	Allen & Company, Invesco & 9 others	74/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
6th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	71/100
7th	Bluebird Bio 1992, Cambridge (United States), Acquired	Developer of gene therapies for severe genetic and rare diseases	$136M	TVM Capital, Forbion & 10 others	71/100
8th	Agios Pharmaceuticals 2008, Cambridge (United States), Public	Developer of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism	$120M	Arch Venture Partners, Flagship Pioneering ... & 6 others	70/100
9th	Rhythm Pharmaceuticals 2010, Boston (United States), Public	Developer of peptide therapeutics for the treatment of rare genetic deficiencies	$84M	Pfizer Venture Investments, Third Rock Ventures ... & 9 others	70/100
10th	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
40th	Stealth BioTherapeutics 2007, Newton (United States), Acquired	Developer of peptide therapy to treat rare mitochondrial diseases and its dysfunction-related disorders	$100M	Sagamore Investment Management, Kingdon Capital Management ... & 8 others	59/100